Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Munich, Germany – August 28 2012: Improved treatment after acute myocardial infarction and less severe patient profile have reduced 30-day mortality over the past 15 years, according to research presented at ESC Congress 2012. The analysis of four French registries from 1995 to 2010 was presented by Professor Nicolas Danchin from the Hopital Européen Georges Pompidou.
Cardiologists recognize two types of myocardial infarction. The first type, ST-elevation myocardial infarction (STEMI), corresponds to the sudden, permanent occlusion of a coronary artery supplying the myocardium (cardiac muscle), usually manifesting as a prolonged, intense chest pain (what is known as a heart attack); it is a true medical emergency, as prompt reopening of the occluded artery will lead to myocardial salvage and limit the consequences of infarction. The second type, non-ST-segment elevation infarction (NSTEMI), is caused by partial or intermittent blockage of an artery, and leads to a more progressive and more limited destruction of myocardial cells; it does not usually require immediate coronary intervention.
“Over the past 15 years, the global picture of acute myocardial infarction has undergone profound changes,” said Professor Danchin. “First, improvements in biological techniques have led to an easier recognition of myocardial cell death, thereby increasing the number of patients with documented myocardial necrosis (i.e. myocardial infarction) considered to have NSTEMI. Second, major changes in patient management have been implemented, following the results of numerous clinical trials in patients with myocardial infarction.”
Every five years since 1995 in France, nationwide surveys of patients admitted to intensive care units for acute myocardial infarction during a one-month period have been implemented. Using data from the four registries from 1995 to 2010, the researchers sought to determine: 1) potential changes in the population of patients with heart attacks; 2) changes in their management; and 3) changes in clinical outcomes.
In all, 10,610 patients participated (1995: 2,152; 2000: 2,320; 2005: 3,059; 2010: 3,079). The proportion of patients with NSTEMI (1995: 29%; 2000: 21%; 2005: 47%; 2010 44%) increased after 2000 because of the generalized use of troponin measurements to detect myocardial necrosis (see figure 1). “Previously these patients would have been considered to have unstable angina,” said Professor Danchin. “The distinction is important because unstable angina usually carries a lower risk than NSTEMI.”
Mean age from 1995 to 2010 remained stable in NSTEMI patients (68 years) and decreased from 66 to 63 years in STEMI patients. From 1995 to 2010 there were increases in the prevalence of obesity (14% to 22%), diabetes (17% to 21%), hypertension (46% to 54%), current smoking (31% to 34%) and hypercholesterolemia (36% to 43%). “Overall, the patient risk profile is less severe in 2010 than in 1995 for both STEMI and NSTEMI patients, although several of the most common risk factors for developing coronary artery disease increased during this time period,” said Professor Danchin.
The initial severity of infarction declined progressively, in particular with fewer patients having signs of heart failure. Professor Danchin said: “This could be because of the efficacy of primary prevention in patients with previously recognised risk factors, or secondary prevention in patients with known coronary artery disease.”
Major changes in management were noted across all types of myocardial infarction. From 1995 to 2010 the use of percutaneous coronary intervention (PCI) increased from 12.5% to 65% in NSTEMI and from 19.5% to 87% in STEMI. In STEMI, the use of emergency reperfusion therapy to reopen the blocked artery increased from 49% to 75%; primary PCI increased from 12% to 60% and fibrinolysis decreased from 37% to 14%. Early use of evidence based medication increased (antiplatelet agents 91% to 97%, beta-blockers 64% to 81%, statins 14 to 90% and ACE inhibitors 46% to 60%). “This shows that the management of all patients with myocardial infarction has improved, with increasing use of recommended interventions and drug therapies,” said Professor Danchin.
Thirty-day mortality dropped during 1995 to 2010 from 12.9% to 3.9% for all acute myocardial infarction patients. It fell from 13.7% to 4.4% in STEMI patients and 10.9% to 3.2% in NSTEMI patients (see figure 2). All in-hospital complications significantly decreased. “Our analysis shows that the early mortality of both STEMI and NSTEMI patients has considerably decreased over the past 15 years,” said Professor Danchin. “Our results suggest that the decreases in 30-day mortality and in-hospital complications are due to both the widespread use of coronary angiography/PCI, and earlier use of recommended medications, and the change in overall clinical presentation of the patients resulting in a decreased intrinsic risk.
Figure 1: Increased proportion of NSTEMI with the generalized use of troponin measurements
Figure 2: Decrease in 30-day mortality according to type of myocardial infarction
Contributors: N. Danchin, E. Puymirat, G. Steg, D. Blanchard, P. Goldstein, M. Hanssen, E. Durand, P. Gueret, T. Simon, JP. Cambou, on behalf of the USIK 1995, USIC 2000, FAST-MI 2005 and FAST-MI 2010 investigators
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2012. The press release has been written by the investigator and edited by the ESC and does not necessarily reflect the opinion of the European Society of Cardiology. Refers to session: Learning from clinical scores and registries in STEMI Refers to press conference: Prevention and outcome after cardiac ischemia
About the European Society of Cardiology The European Society of Cardiology (ESC) represents more than 75,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2012 ESC Congress 2012 will take place from 25 to 29 August at the Messe München centre in Munich, Germany. Information on the scientific programme is available here. More information on ESC Congress 2012 is available from the ESC Press Office or contact us at firstname.lastname@example.org
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved